The platform is designed to modulate multiple targets to achieve beneficial biological effects versus targeting with combinations of molecules. REMD’s technology is based on fusion of an intact monoclonal antibody against one target to a VHH single chain nanobody to a second target to achieve simultaneous activity with good manufacturability and antibody-like pharmacokinetics. REMD’s programs specifically focus on targets where there is improved safety and/or efficacy when the targeting domains are in the same molecule as opposed to where the safety and/or efficacy can be achieved using a combination of 2 molecules.
REMD’s lead SynermAb candidate is REMD-532 which targets PD-1 and
TIGIT and is slated for IND filing in H1 2022. REMD has 3 additional programs
in advanced pre-clinical development.